EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Live-attenuated influenza virus vaccine strain with an engineered temperature-sensitive and genetically stable viral polymerase variant

Tadasuke Naito iD, Hiroshi Ushirogawa, Miyuki Kunishio, Haruka Yano, Susumu Saito, Taisei Higeuchi, Kazuki Fujita, Mineki Saito iD

Journal of Virology · 2025

DOI: 10.1128/jvi.01390-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Virology, 2025. Verfasst von Tadasuke Naito und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Kawasaki Medical School, Okayama, Japan. Hauptthemen laut MEDLINE: Influenza Vaccines, Viral Proteins, Influenza A virus. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development, Mochida Memorial Foundation for Medical and Pharmaceutical Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vaccination against seasonal influenza is considered an effective means of reducing morbidity and mortality. Live-attenuated vaccines offer more protection against influenza than inactivated vaccines as they efficiently induce cellular immunity and provide cross-immunogenicity against various antigenic subtypes. For the production of safer live-attenuated vaccines, it is important to develop a common master donor vaccine strain in which pathogenic revertants are much less likely to appear. In this study, we introduced a single amino acid substitution of Lys471 into the PB1 polymerase subunit of influenza A virus and succeeded in isolating an attenuated mutant virus that exhibits a temperature-sensitive phenotype. The Lys471 residue is located in the polymerase motif D on PB1 and is positioned near the entrance tunnel domain for incoming nucleotide triphosphate. Although 10 viable PB1-Lys471 mutants did not proliferate at 37°C, their variants could replicate at 31°C and 34°C. Moreover, we found that PB1-Lys471Pro variant induces a genetically stable influenza virus phenotype; this mutant virus did not revert to wild-type phenotype from the temperature-sensitive phenotype by serial virus passages. Animal experiments have demonstrated that these PB1 mutant strains work effectively as live-attenuated vaccines. Application of the PB1-Lys471 substitution to a master donor strain is expected to lead to the development of a safer, high-performance, and widely used live-attenuated vaccine with the antigen of circulating influenza viruses. IMPORTANCE Influenza virus elicits respiratory tract disease and is a threat to global human health. Vaccination is considered an effective tool for reducing the morbidity and mortality caused by influenza disease. The only licensed live-attenuated influenza vaccine that has been proven safe and effective is FluMist. In this study, we isolated an attenuated influenza mutant virus with a Lys471 single amino acid substitution in PB1, which displayed a temperature-sensitive and a low-pathogenicity phenotype. By applying the PB1-Lys471 substitution to the vaccine mother strain or the circulating influenza virus using reverse genetic technology, a high-performance and safe live-attenuated vaccine carrying the viral antigens of the vaccine-targeted strain can be developed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Influenza VaccinesViral ProteinsInfluenza A virusVaccines, AttenuatedAnimalsTemperatureAmino Acid SubstitutionMadin Darby Canine Kidney CellsDogsHumansOrthomyxoviridae InfectionsVirus ReplicationMiceInfluenza, HumanMice, Inbred BALB CMutationFemale

Stichwörter der Autor:innen

influenza viruslive-attenuated vaccinereverse genetic analysistemperature-sensitive phenotypeviral RNA polymerase

Substanzen

Influenza VaccinesVaccines, AttenuatedViral Proteinsinfluenza virus polymerase basic protein 1

Autor:innen und Institutionen

  • Department of Microbiology, Kawasaki Medical School, Okayama, Japan.

ORCID-Profile: Tadasuke Naito, Mineki Saito

Förderung

  • Japan Society for the Promotion of Science
  • Japan Agency for Medical Research and Development
  • Mochida Memorial Foundation for Medical and Pharmaceutical Research
  • Takeda Science Foundation
  • Ichiro Kanehara Foundation for the Promotion of Medical Sciences and Medical Care
  • Promotion of Science and Technology in Okayama Prefecture
  • Teraoka Scholarship Foundation
  • Okayama Medical Foundation

Zitieren

APA

Naito, T., Ushirogawa, H., Kunishio, M., Yano, H., Saito, S., Higeuchi, T., Fujita, K., & Saito, M. (2025). Live-attenuated influenza virus vaccine strain with an engineered temperature-sensitive and genetically stable viral polymerase variant. Journal of Virology. https://doi.org/10.1128/jvi.01390-25

Vancouver

Naito T, Ushirogawa H, Kunishio M, Yano H, Saito S, Higeuchi T, et al. Live-attenuated influenza virus vaccine strain with an engineered temperature-sensitive and genetically stable viral polymerase variant. Journal of Virology. 2025. doi:10.1128/jvi.01390-25

BibTeX
@article{Naito2025,
  author = {Naito, Tadasuke and Ushirogawa, Hiroshi and Kunishio, Miyuki and Yano, Haruka and Saito, Susumu and Higeuchi, Taisei and Fujita, Kazuki and Saito, Mineki},
  title = {Live-attenuated influenza virus vaccine strain with an engineered temperature-sensitive and genetically stable viral polymerase variant},
  journal = {Journal of Virology},
  year = {2025},
  doi = {10.1128/jvi.01390-25}
}
Kostenlos starten →